- ►diabetesjournals.org C Menzaghi, V Trischitta, A Doria - Diabetes, 2007 - Am Diabetes Assoc Recent evidence points to molecules secreted by the adipose tissue, or
adipokines, as possible links between increased adipose mass and metabolic
abnormalities. Among these molecules, adiponectin has drawn much attention ... Cited by 53 - Related articles - BL Direct - All 9 versions
- ►endojournals.org JC Florez, KA Jablonski, MW Sun, N Bayley, … - Journal of Clinical Endocrinology & Metabolism, 2007 - Endocrine Soc Context: The common P12A polymorphism in PPARG (a target for thiazolidinedione
medications) has been consistently associated with type 2 diabetes. ...
Objective: We examined whether PPARG P12A affects progression from impaired ... Cited by 42 - Related articles - BL Direct - All 7 versions
HE Lebovitz, MM Austin, L Blonde, JA … - Endocrine Practice, 2006 - AACE Among the more than 20 million Americans who have diabetes, approximately 30% of
the cases are undi- agnosed (1). An additional 42 million people in the United
States have pre-diabetes (impaired glucose tolerance [IGT], impaired ... Cited by 34 - Related articles - All 2 versions
TO Kilpeläinen, TA Lakka, DE LAAKSONEN … - Medicine & Science in Sports & Exercise, 2008 - journals.lww.com TUOMAS O. KILPELA¨ INEN1, TIMO A. LAKKA1,2, DAVID E. LAAKSONEN1,3, JAANA
LINDSTRO¨ M4, JOHAN G. ERIKSSON4,5, TIMO T. VALLE4, HELENA HA¨ MA¨ LA¨
INEN6, PIRJO ILANNE-PARIKKA7,8, SIRKKA KEINA¨ NEN-KIUKAANNIEMI9,10, VIRPI ... Cited by 7 - Related articles - BL Direct - All 3 versions
A Babu, L Fogelfeld - Disease-a-Month, 2006 - Elsevier The clustering of common conditions like hyperglycemia, hypertension, and
dyslipidemia was first brought to attention by Gerald Reaven in the Banting
lecture, 1998, 1 and was called Syndrome X or the Insulin Resistance ... Cited by 5 - Related articles - All 2 versions
AL Gloyn, MI McCarthy - Diabetic Medicine, 2008 - interscience.wiley.com The identification and functional characterisation of genetic variants that
either cause or predispose to diabetes is a major focus of biomedical research.
The molecular basis is now known for the majority of monogenic forms of ... Cited by 3 - Related articles - All 3 versions
CL Aquilante - Pharmacogenomics, 2007 - Future Medicine The thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor-γ
agonists and have glucose-lowering, insulin-sensitizing and anti-inflammatory
effects. TZDs are approved for the treatment of Type 2 diabetes, and have ... Cited by 3 - Related articles - BL Direct - All 4 versions
O Šeda, L Šedová, O Oliyarnyk, L Kazdová, … - Pharmacogenomics, 2008 - Future Medicine * These authors contributed equally to this work. ... Introduction:
Thiazolidinediones are increasingly used drugs for the treatment of Type 2
diabetes. The individual response to thiazolidinedione therapy, ranging ... Cited by 3 - Related articles - BL Direct - All 4 versions
A Vella, M Camilleri - Expert Opin. Pharmacother., 2008 - informahealthcare.com Background: Common genetic variation is associated with increased risk of common
metabolic diseases such as type 1 and type 2 diabetes, and obesity. Increasing
experience with genetic association studies has led to an understanding of ... Cited by 3 - Related articles - BL Direct - All 4 versions
AB Reiss, ME Vagell - Current Medicinal Chemistry, 2006 - ingentaconnect.com Vascular Biology Institute, Department of Medicine, Winthrop-University
Hospital, 222 Station Plaza North, Mineola, NY 11501, USA Abstract: The nuclear
receptor peroxisome proliferator-activated receptor γ (PPARγ) is a ligand- ... Cited by 4 - Related articles
